Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging component...
Zhejiang Huahai Pharmaceutical reported revenue of 9.55 billion CNY for fiscal year 2024, up 14.9% from fiscal year 2023, and net income of 1.12 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 2.15 billion CNY, down 18.3% from a year before. Its largest business segment, Sales of Drug Product, brought in 61% of segment revenue in fiscal year 2024; China was the largest region with 52%.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.